Study of the impact of indacaterol on the individual lives and health status of patients with chronic obstructive pulmonary disease (COPD)

Not Applicable

Completed

• Conditions: Chronic obstructive pulmonary disease (COPD); Respiratory; Other chronic obstructive pulmonary disease

• Registration Number: ISRCTN67880705
• Lead Sponsor: ovartis Pharmaceuticals UK Ltd (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-05-10
• Last Update Posted: 3 July 2017

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Patients with active diagnosis of COPD, confirmed by spirometry, documented in medical notes
2. Patients who are newly-prescribed indacaterol as part of routine clinical practice

Exclusion Criteria

1. Patients who have previously received maintenance therapy for COPD symptoms e.g. Long acting beta agonists (LABAs), long acting antimuscarinics (LAMAs), LABA + inhaled corticosteroid (ICS)
2. Patients unable or unwilling to consent to participation in the study
3. Patients unable or unwilling to complete the study questionnaires
4. Patients who have participated in any interventional clinical trial for indacaterol
5. Patients who have previously been prescribed indacaterol

Study & Design

• Study Type: Observational
• Study Design: Not specified